Evaluation of a cancer-specific comprehensive geriatric assessment (CGA) tool in older women with newly diagnosed primary breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e19518-e19518 ◽  
Author(s):  
R. M. Parks ◽  
L. Hall ◽  
S. Tang ◽  
R. Lakshmanan ◽  
A. Hurria ◽  
...  
2012 ◽  
Vol 106 (6) ◽  
pp. 1247-1247
Author(s):  
S Monfardini ◽  
U Basso ◽  
P Fiduccia ◽  
D Crivellari ◽  
A M Molino ◽  
...  

2017 ◽  
Vol 117 (7) ◽  
pp. 925-931 ◽  
Author(s):  
D O Okonji ◽  
R Sinha ◽  
I Phillips ◽  
D Fatz ◽  
A Ring

2012 ◽  
Vol 10 (1) ◽  
pp. 88 ◽  
Author(s):  
Ruth M Parks ◽  
Radhika Lakshmanan ◽  
Linda Winterbottom ◽  
David AL Morgan ◽  
Karen Cox ◽  
...  

2021 ◽  
Vol 3 (3) ◽  
pp. 49-52
Author(s):  
Ruth Parks ◽  
Kwok-Leung Cheung

The incidence of breast cancer increases with age. Despite this, most research in this field is aimed at the younger patient. Preliminary studies have shown that older women with breast cancer have distinct biological features compared to their younger counterparts. In addition, the focus of treatment of older women may not simply be curative but may be a trade-off between risks of treatment and impact on independence and quality of life. The Nottingham research programme is a unique programme dedicated to primary breast cancer in older women. There are two arms of the research programme 1) determining the biological differences of breast cancer in this cohort 2) exploring the use of geriatric assessment to understand the complex needs and factors contributing to treatment decision making in this group of patients. The overall aim of the research programme is to optimise both the biological and geriatric assessment of older women with primary breast cancer, to provide personalised data at diagnosis, on likely survival and quality of life outcomes following breast cancer treatment. This article will outline why this research programme is important, what it has achieved so far and future aspirations.


Breast Care ◽  
2021 ◽  
pp. 1-6
Author(s):  
Karin Kast ◽  
Julia Häfner ◽  
Evelin Schröck ◽  
Arne Jahn ◽  
Carmen Werner ◽  
...  

<b><i>Background:</i></b> In clinical routine, not every patient who is offered genetic counselling and diagnostics in order to investigate a familial cancer risk predisposition opts for it. Little is known about acceptance of counselling and testing in newly diagnosed breast cancer cases in Germany. <b><i>Methods:</i></b> All primary breast cancer cases and patients with DCIS (ductal carcinoma in situ) treated at the University Hospital of Dresden between 2016 and 2019 were included. The number of tumor board recommendations for genetic counselling on the basis of the GC-HBOC risk criteria was recorded. Acceptance was analyzed by number of cases with counselling in the GC-HBOC-Center Dresden. <b><i>Results:</i></b> Of 996 primary breast cancer and DCIS cases, 262 (26.3%) were eligible for genetic counselling. Recommendation for genetic counselling was accepted by 64.1% (168/262). Of these 90.5% (152/168) opted for molecular genetic analysis. The acceptance rate for counselling increased between 2016 and 2019 from 58.3 to 72.6%. Altogether, 20.4% (31/152) patients were found to carry a pathogenic variant in the breast cancer genes <i>BRCA1</i> or <i>BRCA2</i>. <b><i>Conclusion:</i></b> Acceptance of recommendation is increasing as clinical consequences augment. Optimization in providing information about hereditary cancer risk and in accessibility of counselling and testing is required to further improve acceptance of recommendation.


Sign in / Sign up

Export Citation Format

Share Document